Mereo BioPharma Group (ADR) (MREO)
Advances acquired rare-disease drug candidates through clinical development and partnerships.
Something off on this page? Send us feedback.
Develops setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Clinically advanced assets are acquired and advanced through partnerships, with setrusumab commercial rights retained in Europe and the U.K.
Develops setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Both programs reflect an asset-selection model: clinically advanced candidates are acquired after larger drugmakers deprioritize them, then advanced through scientific, commercial, and collaboration capabilities.
Setrusumab is partnered with Ultragenyx, while commercial rights in Europe and the U.K. are retained. Other candidates came from Novartis, AstraZeneca, and the OncoMed transaction, leaving a portfolio of partnered or partner-seeking programs rather than a discovery-led platform.
Clinical-trial enrollment, potential product-market size, key executives, and continued Nasdaq listing compliance shape execution. Certain pre-commercial and manufacturing activities for setrusumab were curtailed or delayed after top-line trial data.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 19, 2026 | JP Morgan | Downgrade | ||
| Mar 23, 2026 | JP Morgan | Downgrade | ||
| Dec 30, 2025 | Jefferies | Downgrade | Target: — | Target: $0.50 |
| Dec 29, 2025 | Robert W. Baird | Target | Target: $8 | Target: $1 |
| Dec 29, 2025 | BTIG | Reiterate | Rating: —Target: $6 | Target: $1 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.1M · Total debt $1.0M · Total assets $34.7M · Shareholders' equity $28.7M
- Revenue
- $0
- Operating income
- −$7.0M
- Net income
- −$7.0M
No dividends on record.
| Institutions | 35.45% | 56.61M ADS | |
|---|---|---|---|
| 63 holders · as of Jun 30, 2026 | |||
| Strategic holders | 1.18% | 1.88M ADS | |
| 1 holder · as of Feb 11, 2022 | |||
| Other | 63.37% | 101.20M ADS | |
| remainder | |||
159.69M ADS (1 ADS = 5 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Rubric Capital Management LPInstitution | 9.59% | 15.31M ADS | as of Jun 30, 2026 |
683 Capital Management, LLCInstitution | 7.38% | 11.78M ADS | as of Jun 30, 2026 |
Bank of America Corp /DE/Institution | 5.13% | 8.20M ADS | as of Jun 30, 2026 |
Defilade Capital Management, L.P.Institution | 4.73% | 7.56M ADS | as of Jun 30, 2026 |
Newtyn Management, LLCInstitution | 1.88% | 3.00M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Amgen
Late-stage anti-sclerostin therapy for pediatric OI
- Grifols (ADR)
Marketed IV AAT augmentation therapy for severe AATD
- Takeda (ADR)
Marketed IV AAT therapies for severe AATD
- Kamada
GLASSIA supply and marketing exposure in AATD augmentation
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mereo BioPharma Group (ADR) | $0.3545 | +12.08% | $50.5M | — | — | — | — |
| Amgen | $406.78 | −0.84% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Grifols (ADR) | $7.28 | −2.15% | $6.29B | 9.7 | — | 0.7 | −1.8% |
| Takeda (ADR) | $18.81 | −0.74% | $60.30B | 52.9 | 59.8 | 2.0 | +4.2% |
| Kamada | $8.75 | −1.41% | $511.7M | 23.4 | 17.3 | 2.7 | +22.7% |
| Median | 24.5 | 17.3 | 2.4 | +6.9% |